Addex Therapeutics to Participate at the Biotechgate Digital Partnering Conference
August 31, 2020 01:00 ET
|
Addex Therapeutics
Geneva, Switzerland, August 31, 2020 - Addex Therapeutics Ltd (SIX and Nasdaq: ADXN), a leading company pioneering allosteric modulation-based drug discovery and development today announced that that...
Addex and the SIB Swiss Institute of Bioinformatics Receive Innosuisse Grant to Repurpose Potent Dopamine Antagonist Using Computational Modelling
August 27, 2020 01:00 ET
|
Addex Therapeutics
ADX10061 Previously Demonstrated Favorable Safety and Tolerability in Clinical Studies Geneva, Switzerland, August 27, 2020 – Addex Therapeutics (SIX: ADXN and Nasdaq: ADXN), a clinical-stage...
Addex Reports 2020 Half Year Financial Results and Provides Corporate Update
August 12, 2020 01:00 ET
|
Addex Therapeutics
Geneva, Switzerland, August 12, 2020 – Addex Therapeutics (SIX: ADXN and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development,...
Addex Therapeutics to Release Half-Year 2020 Financial Results and Host Conference Call on August 12, 2020
August 10, 2020 01:00 ET
|
Addex Therapeutics
Geneva, Switzerland, August 10, 2020 – Addex Therapeutics Ltd (SIX and Nasdaq: ADXN), a leading company pioneering allosteric modulation-based drug discovery and development, will discuss its...
Addex Therapeutics to Participate in the BTIG Virtual Biotechnology Conference 2020
August 06, 2020 01:00 ET
|
Addex Therapeutics
Geneva, Switzerland, August 6, 2020 - Addex Therapeutics Ltd (SIX and Nasdaq: ADXN), a leading company pioneering allosteric modulation-based drug discovery and development, today announced that Tim...
Van Leeuwenhoeck Issues Updated Addex Equity Research Report
July 20, 2020 01:00 ET
|
Addex Therapeutics
Geneva, Switzerland, July 20, 2020 – Addex Therapeutics (SIX: ADXN), a leading company pioneering allosteric modulation-based drug discovery and development today announced that the independent life...
Addex mGlu2 PAM Program to Advance into Epilepsy Phase 2a Proof of Concept Clinical Study
June 16, 2020 01:00 ET
|
Addex Therapeutics
Study with JNJ-40411813 (ADX71149) will treat first epilepsy patients in early 2021 Geneva, Switzerland, June 16, 2020 – Addex Therapeutics (SIX: ADXN and Nasdaq: ADXN), a clinical-stage...
Addex Shareholders Approve All Resolutions at Annual General Meeting
June 10, 2020 01:00 ET
|
Addex Therapeutics
Geneva, Switzerland, 10 June 2020 – Addex Therapeutics (SIX: ADXN), a leading company pioneering allosteric modulation-based drug discovery and development, announced today that its shareholders...
Addex Reports Q1 2020 Financial Results and Provides Corporate Update
May 20, 2020 01:00 ET
|
Addex Therapeutics
Geneva, Switzerland, May 20, 2020 – Addex Therapeutics (SIX: ADXN and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development,...
Addex Therapeutics Establishes Scientific Advisory Board
May 19, 2020 01:00 ET
|
Addex Therapeutics
World-leading experts will support our strategic decision-making processes as we continue advancing our pipeline of allosteric modulators Geneva, Switzerland, May 19, 2020 - Addex Therapeutics...